DP
RYTM icon

Diadema Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Diadema Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$2.65M – 125
2025
Q1 		$2.65M Sell
50,000
-25,000
-33% -$1.39M 0.69% 34
2024
Q4 		$4.2M Buy
+75,000
New +$4.14M 1.8% 15

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Diadema Partners's RYTM Position: Q2 2025 in Review

Diadema Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 50,000 shares — an estimated $2.65M sold.

Diadema Partners first reported a position in RYTM in Q4 2024 and held it in 2 quarters. The position peaked at $4.2M in Q4 2024. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

  • Diadema Partners reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Diadema Partners sold 50,000 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $2.65M.
  • Diadema Partners first reported a position in Rhythm Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Diadema Partners's Rhythm Pharmaceuticals position peaked at $4.2M in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.